Abstract 7P
Background
Stereotactic vacuum-assisted breast biopsy (SVAB) is widely used to evaluate predominantly mammograhic microcalcifications without specific ultrasound abnormalities. Recently however, there raise the problem that screening mammography detect the indolent low grade ductal carcinoma in situ (DCIS), and such diseases don’t necessarily have to be diagnosed by invasive SVAB examination. Moreover, breast magnetic resonance imaging (MRI) has increasingly been performed over the past 10 years and reveals high sensitivity for detecting breast cancer, especially tumor undetectable by ultrasound. The purpose of this study was to assess the optimal indications for SVAB.
Methods
Five hundred and eighty-one patients with mammographic microcalcifications underwent SVAB between 2008 and 2014 in our hospital. All calcification lesions were classified into several groups according to the calcification categories (CC) and the presence of suspicions MRI abnormalities. We examined the rate of malignant disease in the subgroups. BI-RADS 4 and 5 MRI lesions were defined as suspicious MRI abnormality (SMA). We considered high grade DCIS and invasive ductal carcinoma (IDC) as worrisome disease ought to be diagnosed.
Results
The rate of malignancy was 6.3 % in CC2, 14.3% in CC3, 30.3% in CC4, and 80.0% in CC5 altogether. Of 581 patients, two hundred and thirty-three patients were underwent contrast enhanced MRI. Among category 3 or 4 microcalcifications without SMA (134 lesions), results of SVAB revealed 22 malignant lesions (16.4%), including 21 low grade DCIS and only one high grade DCIS and no IDC. If the lesions were accompanied by SMA, the rate of malignancy in these categories was increased to 66.2% (51/77), including 8 high grade DCIS and 14 IDC. If the regions were classified to category 5, about three forth cases were accompanied by SMA (17/23). Half of the category 5 lesions without SMA was malignant (3/6), including one high grade DCIS.Table: 7P
MRI (-) | MRI (-) | MRI (-) | MRI (+) | MRI (+) | MRI (+) | |
---|---|---|---|---|---|---|
category 3 | category 4 | category 5 | category 3 | category 4 | category 5 | |
Benign | 75 | 33 | 3 | 17 | 6 | 0 |
ADH | 4 | 0 | 0 | 1 | 2 | 0 |
Low grade DCIS | 13 | 8 | 2 | 11 | 18 | 6 |
High grade DCIS | 1 | 0 | 1 | 3 | 5 | 5 |
IDC | 0 | 0 | 0 | 6 | 8 | 8 |
Conclusions
Mammographic microcalcification classified as 3 or 4 without suspicious MRI abnormal lesion were not be recommended for stereotactic vacuum-assisted biopsies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Naoki Sato.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
185P - Evaluation of the effect of cholesorption on the concentration of TNF-α in the serum of the blood in tumours of the biliopancreatoduodenal zone
Presenter: Marufjon Salokhiddinov
Session: Poster display session
Resources:
Abstract
186P - Efficacy and safety of sorafenib following hepatic resection in patients with hepatocellular carcinoma: A meta-analysis
Presenter: Yang Yuan
Session: Poster display session
Resources:
Abstract
187P - Correlation between spleenic dose and grade of hematological toxicity in chemoradiation of stomach
Presenter: Umesh Velu
Session: Poster display session
Resources:
Abstract
188P - Survival and prognostic factors in cholangiocarcinoma: A single-center experience
Presenter: Sonngwit Payapwattanawong
Session: Poster display session
Resources:
Abstract
189P - Stereotactic body radiotherapy in primary hepatocellular carcinoma and oligometastatis to liver: A single Institution experience
Presenter: Sayan Paul
Session: Poster display session
Resources:
Abstract
190P - Details of response with first-line gemcitabine and nab-paclitaxel therapy in patients with advanced pancreatic cancer
Presenter: Yusuke Nagata
Session: Poster display session
Resources:
Abstract
191P - Assessment of efficacy and safety of sorafenib versus no treatment in Egyptian hepatocellular carcinoma patients
Presenter: Noha El Baghdady
Session: Poster display session
Resources:
Abstract
192P - Clinical importance of the determination of interleukin-6 in bile and blood in tumours of biliopancreatoduodenal zone
Presenter: Marufjon Salokhiddinov
Session: Poster display session
Resources:
Abstract
193P - Metastatic carcinoma gall bladder: A clinicoepidemiological profile of Indian patients
Presenter: Anvesh Rathore
Session: Poster display session
Resources:
Abstract
195P - HGCSG1601: A retrospective cohort study of the efficacy and safety of nab-paclitaxel plus gemcitabine (nab-P+GEM) for unresectable locally advanced pancreatic cancer (LAPC)
Presenter: Aya Tanimoto
Session: Poster display session
Resources:
Abstract